Skip to main navigation Skip to main content
info(at)avldigital.remove-this.de
Deutsch English
Narrow Search
Search narrowed by
Last searches

Results for *

Displaying results 1 to 4 of 4.

  1. Brazilian competition law and access to health in Brazil
    exploitative pricing in the pharmaceutical sector
    Author: Castro, Bruno Braz de
    Published: [2022]
    Publisher:  South Centre, Geneva

    This paper aims to analyze the interfaces between Brazilian Competition Law and the issue of access to medicines, with a special focus on abuse of industrial property rights and related exclusionary and exploitative effects. The paper analyzes the... more

    Access:
    Verlag (kostenfrei)
    Verlag (kostenfrei)
    Resolving-System (kostenfrei)

    Location:
    Max-Planck-Institut für Innovation und Wettbewerb / Max-Planck-Institut für Steuerrecht und Öffentliche Finanzen, Bibliothek
    Inter-library loan:
    No inter-library loan

     

    This paper aims to analyze the interfaces between Brazilian Competition Law and the issue of access to medicines, with a special focus on abuse of industrial property rights and related exclusionary and exploitative effects. The paper analyzes the case law of Brazilian Administrative Council for Economic Defense (CADE) in the pharmaceutical sector and discusses abusive practices such as illegitimately imposing non-existent or invalid intellectual property rights with anticompetitive purposes. It then addresses abusive strategies in the exercise of industrial property rights which are, in essence, valid: i.e., exclusionary practices, aimed at artificially raising barriers to entry; and exploitative practices, directly translated as the exercise of market power to the detriment of the consumer. The latter ultimately result in exploitative excessive prices; contractual, quality or privacy degradation; and restrictions on supply, such as by hoarding/preventing the exploitation of industrial property rights. The paper concludes that the prohibition of exploitative pricing under the current competition law is legally valid and effective, with certain methodological concerns towards reducing the risk of wrongful convictions (for instance, by applying screening tests to determine the markets that are candidates for intervention). In view of such guidelines, the pharmaceutical industry appears to be an important candidate for antitrust attention, given the magnitude of the harm potentially derived from non-intervention against the practice. Remedies in this area, importantly, should focus on identifying and solving the sector's structural competitive problems. In the case of medicines subject to price regulation by the Drug Market Regulation Chamber (CMED), the technical expertise of the competition authority may be of great value in terms of competition advocacy, a fact that is demonstrated in light of recent discussions on extraordinary price adjustments because of competitive problems in certain markets.

     
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Online
    Series: Research paper / South Centre ; 143 (11 January 2022)
    Other subjects: Access to Healthcare; Access to Medicines; Antitrust; Brazil; Competition; Competition Law; Competition Policy; Competition Regulation; COVID-19; Health; Industrial Property; Industrial Property Rights; Intellectual Property; Intellectual Property Rights (IPRs); Pandemic; Pharmaceuticals; Graue Literatur
    Scope: 1 Online-Ressource (ca. 58 Seiten)
  2. Direito brasileiro da concorrência e acesso à saúde no Brasil
    preços exploratórios no setor de medicamentos
    Author: Castro, Bruno Braz de
    Published: [2022]
    Publisher:  South Centre, Genebra, Suíça

    This paper aims to analyze the interfaces between Brazilian Competition Law and the issue of access to medicines, with special focus on abuses of industrial property rights in their exclusionary and exploitative effects. The paper analyzes the case... more

    Access:
    Verlag (kostenfrei)
    Verlag (kostenfrei)
    Resolving-System (kostenfrei)

    Location:
    Max-Planck-Institut für Innovation und Wettbewerb / Max-Planck-Institut für Steuerrecht und Öffentliche Finanzen, Bibliothek
    Inter-library loan:
    No inter-library loan

     

    This paper aims to analyze the interfaces between Brazilian Competition Law and the issue of access to medicines, with special focus on abuses of industrial property rights in their exclusionary and exploitative effects. The paper analyzes the case law of the Brazilian Administrative Council for Economic Defense (CADE) in the medicines sector and discusses the abuses aiming at the illegitimate imposition of non-existent or invalid intellectual property rights with anticompetitive purposes. It then addresses the abuses in the exercise of industrial property rights that are, in themselves, valid: exclusionary practices aimed at artificially raising barriers to entry, and exploitative practices, directly translated into the exercise of market power to the detriment of the consumer. The latter are turned into exploitative excessive prices, contractual degradations, quality or privacy degradations, as well as restrictions on supply such as hoarding/impediment to the exploitation of industrial property rights. The paper concludes that the prohibition of exploitative pricing under the current competition law is legally valid and effective, with certain methodological concerns in order to minimize the risk of wrongful convictions (such as the construction of "screening" tests of markets that are candidates for intervention). In view of such guidelines, the pharmaceutical industry appears to be an important candidate for antitrust attention, given the magnitude of the damages potentially derived from the non-intervention on the practice. Remedies in this area, importantly, should focus on identifying and solving the sector’s structural competitive problems. In the case of drugs subject to price regulation by the Drugs Market Regulation Chamber (CMED), the technical expertise of the competition authority may be of great value in competition advocacy, which is demonstrated in light of the recent discussions about extraordinary price adjustments due to competitive problems in a given market.

     
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: Portuguese
    Media type: Book
    Format: Online
    Series: Research paper / South Centre ; 143 (11 de janeiro de 2022)
    Other subjects: Access to Healthcare; Access to Medicines; Antitrust; Brazil; Competition; Competition Law; Competition Policy; Competition Regulation; COVID-19; Health; Industrial Property; Industrial Property Rights; Intellectual Property; Intellectual Property Rights (IPRs); Pandemic; Pharmaceuticals; Graue Literatur
    Scope: 1 Online-Ressource (ca. 58 Seiten)
  3. Brazilian competition law and access to health in Brazil
    exploitative pricing in the pharmaceutical sector
    Author: Castro, Bruno Braz de
    Published: [2022]
    Publisher:  South Centre, Geneva

    This paper aims to analyze the interfaces between Brazilian Competition Law and the issue of access to medicines, with a special focus on abuse of industrial property rights and related exclusionary and exploitative effects. The paper analyzes the... more

    Access:
    Verlag (kostenfrei)
    Verlag (kostenfrei)
    Resolving-System (kostenfrei)

    Location:
    Universitätsbibliothek Braunschweig
    Inter-library loan:
    No inter-library loan

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Signature:
    DS 751
    Inter-library loan:
    No inter-library loan

     

    This paper aims to analyze the interfaces between Brazilian Competition Law and the issue of access to medicines, with a special focus on abuse of industrial property rights and related exclusionary and exploitative effects. The paper analyzes the case law of Brazilian Administrative Council for Economic Defense (CADE) in the pharmaceutical sector and discusses abusive practices such as illegitimately imposing non-existent or invalid intellectual property rights with anticompetitive purposes. It then addresses abusive strategies in the exercise of industrial property rights which are, in essence, valid: i.e., exclusionary practices, aimed at artificially raising barriers to entry; and exploitative practices, directly translated as the exercise of market power to the detriment of the consumer. The latter ultimately result in exploitative excessive prices; contractual, quality or privacy degradation; and restrictions on supply, such as by hoarding/preventing the exploitation of industrial property rights. The paper concludes that the prohibition of exploitative pricing under the current competition law is legally valid and effective, with certain methodological concerns towards reducing the risk of wrongful convictions (for instance, by applying screening tests to determine the markets that are candidates for intervention). In view of such guidelines, the pharmaceutical industry appears to be an important candidate for antitrust attention, given the magnitude of the harm potentially derived from non-intervention against the practice. Remedies in this area, importantly, should focus on identifying and solving the sector's structural competitive problems. In the case of medicines subject to price regulation by the Drug Market Regulation Chamber (CMED), the technical expertise of the competition authority may be of great value in terms of competition advocacy, a fact that is demonstrated in light of recent discussions on extraordinary price adjustments because of competitive problems in certain markets.

     
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Online
    Other identifier:
    hdl: 10419/270388
    Series: Research paper / South Centre ; 143 (11 January 2022)
    Subjects: Access to Healthcare; Access to Medicines; Antitrust; Brazil; Competition; Competition Law; Competition Policy; Competition Regulation; COVID-19; Health; Industrial Property; Industrial Property Rights; Intellectual Property; Intellectual Property Rights (IPRs); Pandemic; Pharmaceuticals
    Scope: 1 Online-Ressource (circa 58 Seiten)
  4. Direito brasileiro da concorrência e acesso à saúde no Brasil
    preços exploratórios no setor de medicamentos
    Author: Castro, Bruno Braz de
    Published: [2022]
    Publisher:  South Centre, Genebra, Suíça

    This paper aims to analyze the interfaces between Brazilian Competition Law and the issue of access to medicines, with special focus on abuses of industrial property rights in their exclusionary and exploitative effects. The paper analyzes the case... more

    Access:
    Verlag (kostenfrei)
    Verlag (kostenfrei)
    Resolving-System (kostenfrei)

    Location:
    Universitätsbibliothek Braunschweig
    Inter-library loan:
    No inter-library loan

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Signature:
    DS 751
    Inter-library loan:
    No inter-library loan

     

    This paper aims to analyze the interfaces between Brazilian Competition Law and the issue of access to medicines, with special focus on abuses of industrial property rights in their exclusionary and exploitative effects. The paper analyzes the case law of the Brazilian Administrative Council for Economic Defense (CADE) in the medicines sector and discusses the abuses aiming at the illegitimate imposition of non-existent or invalid intellectual property rights with anticompetitive purposes. It then addresses the abuses in the exercise of industrial property rights that are, in themselves, valid: exclusionary practices aimed at artificially raising barriers to entry, and exploitative practices, directly translated into the exercise of market power to the detriment of the consumer. The latter are turned into exploitative excessive prices, contractual degradations, quality or privacy degradations, as well as restrictions on supply such as hoarding/impediment to the exploitation of industrial property rights. The paper concludes that the prohibition of exploitative pricing under the current competition law is legally valid and effective, with certain methodological concerns in order to minimize the risk of wrongful convictions (such as the construction of “screening” tests of markets that are candidates for intervention). In view of such guidelines, the pharmaceutical industry appears to be an important candidate for antitrust attention, given the magnitude of the damages potentially derived from the non-intervention on the practice. Remedies in this area, importantly, should focus on identifying and solving the sector’s structural competitive problems. In the case of drugs subject to price regulation by the Drugs Market Regulation Chamber (CMED), the technical expertise of the competition authority may be of great value in competition advocacy, which is demonstrated in light of the recent discussions about extraordinary price adjustments due to competitive problems in a given market.

     
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: Portuguese
    Media type: Book
    Format: Online
    Other identifier:
    hdl: 10419/262116
    Series: Research paper / South Centre ; 143 (11 de janeiro de 2022)
    Subjects: Access to Healthcare; Access to Medicines; Antitrust; Brazil; Competition; Competition Law; Competition Policy; Competition Regulation; COVID-19; Health; Industrial Property; Industrial Property Rights; Intellectual Property; Intellectual Property Rights (IPRs); Pandemic; Pharmaceuticals
    Scope: 1 Online-Ressource (circa 58 Seiten)